Literature DB >> 27393744

Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing.

A Owusu Obeng1,2, T Kaszemacher3, N S Abul-Husn3, O Gottesman3, A Vega4, E Waite4, K Myers5, J Cho3,6,7, E P Bottinger3,8, S B Ellis3, S A Scott9,10.   

Abstract

Implementation of pharmacogenetic-guided warfarin dosing has been hindered by inconsistent results from reported clinical trials and a lack of available algorithms that include alleles prevalent in non-white populations. However, current evidence indicates that algorithm-guided dosing is more accurate than empirical dosing. To facilitate multiethnic algorithm-guided warfarin dosing using preemptive genetic testing, we developed a strategy that accounts for the complexity of race and leverages electronic health records for algorithm variables and deploying point-of-care dose recommendations.
© 2016 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27393744      PMCID: PMC5638436          DOI: 10.1002/cpt.425

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

Authors:  J A Johnson; L Gong; M Whirl-Carrillo; B F Gage; S A Scott; C M Stein; J L Anderson; S E Kimmel; M T M Lee; M Pirmohamed; M Wadelius; T E Klein; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-09-07       Impact factor: 6.875

2.  The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics.

Authors:  O Gottesman; S A Scott; S B Ellis; C L Overby; A Ludtke; J-S Hulot; J Hall; K Chatani; K Myers; J L Kannry; E P Bottinger
Journal:  Clin Pharmacol Ther       Date:  2013-04-03       Impact factor: 6.875

3.  Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations.

Authors:  M A Perera; L H Cavallari; J A Johnson
Journal:  Clin Pharmacol Ther       Date:  2014-03       Impact factor: 6.875

4.  Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?

Authors:  Stuart A Scott; Steven A Lubitz
Journal:  Pharmacogenomics       Date:  2014-04       Impact factor: 2.533

5.  Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems.

Authors:  L J Rasmussen-Torvik; S C Stallings; A S Gordon; B Almoguera; M A Basford; S J Bielinski; A Brautbar; M H Brilliant; D S Carrell; J J Connolly; D R Crosslin; K F Doheny; C J Gallego; O Gottesman; D S Kim; K A Leppig; R Li; S Lin; S Manzi; A R Mejia; J A Pacheco; V Pan; J Pathak; C L Perry; J F Peterson; C A Prows; J Ralston; L V Rasmussen; M D Ritchie; S Sadhasivam; S A Scott; M Smith; A Vega; A A Vinks; S Volpi; W A Wolf; E Bottinger; R L Chisholm; C G Chute; J L Haines; J B Harley; B Keating; I A Holm; I J Kullo; G P Jarvik; E B Larson; T Manolio; C A McCarty; D A Nickerson; S E Scherer; M S Williams; D M Roden; J C Denny
Journal:  Clin Pharmacol Ther       Date:  2014-06-24       Impact factor: 6.875

  5 in total
  3 in total

Review 1.  Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai.

Authors:  Stuart A Scott; Aniwaa Owusu Obeng; Mariana R Botton; Yao Yang; Erick R Scott; Stephen B Ellis; Richard Wallsten; Tom Kaszemacher; Xiang Zhou; Rong Chen; Paola Nicoletti; Hetanshi Naik; Eimear E Kenny; Aida Vega; Eva Waite; George A Diaz; Joel Dudley; Jonathan L Halperin; Lisa Edelmann; Andrew Kasarskis; Jean-Sébastien Hulot; Inga Peter; Erwin P Bottinger; Kurt Hirschhorn; Pamela Sklar; Judy H Cho; Robert J Desnick; Eric E Schadt
Journal:  Pharmacogenomics       Date:  2017-10-06       Impact factor: 2.533

Review 2.  Personalized Medicine and the Power of Electronic Health Records.

Authors:  Noura S Abul-Husn; Eimear E Kenny
Journal:  Cell       Date:  2019-03-21       Impact factor: 41.582

3.  Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population.

Authors:  LiQun Jia; Zanxin Wang; Jianlong Men; Heng Cai; Minxin Wei
Journal:  Ther Clin Risk Manag       Date:  2017-03-31       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.